Oncologie is a biopharmaceutical company based in Boston and Shanghai that uses proprietary biomarkers to guide development of next‑generation oncology therapeutics. Led by founder and CEO Laura E. Benjamin, PhD, the company’s pipeline focuses on mid‑stage programs that modify the immune system to enhance efficacy of current standards of care and emerging immunotherapy agents. It closed an $80M Series B to advance its three clinical‑stage programs, expand its biomarker platform and pursue in‑licensing opportunities. Oncologie plans to initiate key clinical trials in the coming months, notably a global proof‑of‑concept gastric cancer study of its lead compound bavituximab in combination with pembrolizumab. Bavituximab is an investigational immune‑modulatory monoclonal antibody that targets phosphatidylserine to help immune cells recognize and fight tumors. Other programs include a TLR9 activator, lefitolimod, and a VEGF‑targeting antibody, varisacumab. Oncologie is a Boston and Shanghai–based biopharmaceutical company developing cancer therapies aimed at improving long-term patient survival. The company is building a pipeline of clinical-stage drug candidates through licensing and partnering. Its programs are designed to combine with immune checkpoint inhibitors to improve survival benefits and include multiple global programs currently in Phase 2 and Phase 3. Oncologie plans to leverage recent regulatory changes in China to conduct parallel clinical development in China and the U.S., with the goal of bringing innovative immuno-oncology products to both markets simultaneously. The company is led by Founder, President, and CEO Dr. Laura Benjamin. In 2018 it raised $16.5M in seed funding to support these clinical and development activities.

Total raised

$97M

Funding rounds

2

Latest round

Series B

Latest activity

Jun 2019